CliffBio
small molecule

EFAVIRENZ

EFAVIRENZ

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameEFAVIRENZ
Active ingredientEFAVIRENZ
Strength600MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2018
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

EFAVIRENZ patent cliff — loss of exclusivity — | CliffBio